This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
C3 Souvenir Holding, Inc. completed the acquisition of Verdelite Sciences, Inc. from Emerald Health Therapeutics, Inc. CI
C3 Souvenir Holding, Inc. entered into a share purchase agreement to acquire Verdelite Sciences, Inc. from Emerald Health Therapeutics, Inc. for CAD 12 million. CI
Skye Bioscience, Inc. completed the acquisition of Emerald Health Therapeutics, Inc. from Emerald Health Sciences Inc. and others. CI
Emerald Health Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Skye Bioscience Reports that CSE-listed Emerald Health Therapeutics Shareholders Voted in Favor of Plan of Arrangement MT
Transcript : Emerald Health Therapeutics, Inc. - Shareholder/Analyst Call
Certain Emerald Health Shareholders Oppose Proposed Merger with Skye Biosciences MT
Emerald Health Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Emerald Health Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Emerald Health Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt CI
Skye Bioscience, Inc. entered into term sheet to acquire Emerald Health Therapeutics, Inc. from Emerald Health Sciences Inc. and others for CAD 24.4 million. CI
Emerald Health Therapeutics, Inc. Approves Board Appointments CI
Transcript : Emerald Health Therapeutics, Inc. - Shareholder/Analyst Call
Emerald Health Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
An unknown buyer agreed to acquire Recreational and Medical Cannabis Business of Emerald Health Therapeutics, Inc. CI
Emerald Health Therapeutics, Inc. and HYTN Cannabis to Launch Cannabis Beverages in Canada CI
Jenn Hepburn Steps Down as Chief Financial Officer of Emerald Health Therapeutics, Inc., effective October 15, 2021 CI
Transcript : Emerald Health Therapeutics, Inc., Q2 2021 Earnings Call, Aug 31, 2021
Emerald Health Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Emerald Health Therapeutics, Inc Appoints Nick Mosgrove as VP Sales & Marketing CI
Emerald Health Therapeutics, Inc. Announces Resignation of Avtar Dhillon as Director and Executive Chairman of its Board of Directors CI
Emerald Health Therapeutics, Inc. Launches Fuse™ Lifestyle Brand with Fast-Acting Cannabis-Infused Beverage CI
Emerald Health Therapeutics : Tbd30's Manager Takes Stabilization Measures Following Stockholm Listing MT
Emerald Health Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
The Uplifers's PRIMA announced that it has received $9.2 million in funding from a group of investors CI
Chart Emerald Health Therapeutics
More charts
Emerald Health Therapeutics, Inc. is a Canada-based company, which is engaged in the business of production, distribution, and sale of cannabis products in Canada. The Company's segments include Cannabis and Other. It primarily operates in the Cannabis segment. It provides recreational, medical and wellness-oriented cannabis products. It offers products through brands, including SYNC Wellness, Fuse, whole-flower cannabis, Souvenir and Health Therapeutics. Its SYNC Wellness products include nanoemulsions and cannabis oils. Its Fuse product include nanoemulsion shots. Its whole-flower cannabis products consist of dried cannabis and pre-rolled cannabis. Its Souvenir product is dried flower, which is hang-dried and hand-packaged to optimize terpene profiles. Its Health Therapeutics offers medical products. Its subsidiaries include Emerald Health Therapeutics Canada Inc., Emerald Health Naturals Inc., Avalite Sciences Inc., Verdelite Sciences Inc., and Verdelite Property Holdings Inc.
Sector
-
More about the company
  1. Stock Market
  2. Equities
  3. EMH Stock
  4. News Emerald Health Therapeutics
  5. Skye Bioscience Reports that CSE-listed Emerald Health Therapeutics Shareholders Voted in Favor of Plan of Arrangement